AR062647A1 - Formulaciones farmaceutica y metodos de uso - Google Patents
Formulaciones farmaceutica y metodos de usoInfo
- Publication number
- AR062647A1 AR062647A1 ARP060100226A ARP060100226A AR062647A1 AR 062647 A1 AR062647 A1 AR 062647A1 AR P060100226 A ARP060100226 A AR P060100226A AR P060100226 A ARP060100226 A AR P060100226A AR 062647 A1 AR062647 A1 AR 062647A1
- Authority
- AR
- Argentina
- Prior art keywords
- pregabalin
- gabapentin
- active ingredient
- group
- ingredient selected
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 8
- 229960002870 gabapentin Drugs 0.000 abstract 4
- 229960001233 pregabalin Drugs 0.000 abstract 4
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64585705P | 2005-01-21 | 2005-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062647A1 true AR062647A1 (es) | 2008-11-26 |
Family
ID=36692870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100226A AR062647A1 (es) | 2005-01-21 | 2006-01-20 | Formulaciones farmaceutica y metodos de uso |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1838291A4 (fr) |
| JP (1) | JP2008528494A (fr) |
| KR (1) | KR20070116588A (fr) |
| CN (1) | CN101137352A (fr) |
| AR (1) | AR062647A1 (fr) |
| AU (1) | AU2006206423A1 (fr) |
| BR (1) | BRPI0614021A2 (fr) |
| CA (1) | CA2595470A1 (fr) |
| IL (1) | IL184735A0 (fr) |
| MX (1) | MX2007008833A (fr) |
| TW (1) | TW200640497A (fr) |
| WO (1) | WO2006078811A2 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2125021E (pt) | 2006-12-22 | 2011-07-26 | Recordati Ireland Ltd | Terapia de combinação de distúrbios do tracto urinário inferior com 2 ligandos e nsaid |
| EP2018854A1 (fr) * | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Nouvelles combinaisons de néramexane pour le traitement des troubles neuro-dégénératifs |
| PL2596784T3 (pl) * | 2007-11-23 | 2017-06-30 | Grünenthal GmbH | Kompozycje tapentadolu |
| US8454993B2 (en) | 2007-11-23 | 2013-06-04 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| LT2661266T (lt) | 2011-01-07 | 2020-12-10 | Anji Pharma (Us) Llc | Gydimo būdai chemosensorinio receptoriaus ligando pagrindu |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| EP2704698B1 (fr) * | 2011-05-05 | 2019-10-02 | Hennig Arzneimittel GmbH&Co. Kg | Forme galénique pour libération ciblée de principes actifs |
| KR101438546B1 (ko) * | 2011-08-26 | 2014-09-17 | 근화제약주식회사 | 프레가발린을 포함하는 서방성 제제 |
| WO2013100873A1 (fr) * | 2011-12-19 | 2013-07-04 | Mahmut Bilgic | Formulation pharmaceutique de prégabaline (taille de particules 300-2500 micromètres) |
| CN104349773A (zh) * | 2012-01-06 | 2015-02-11 | 埃尔舍利克斯治疗公司 | 用于治疗代谢性病症的组合物和方法 |
| KR20230095124A (ko) | 2012-01-06 | 2023-06-28 | 앤지 파마 유에스 엘엘씨 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| KR102221846B1 (ko) * | 2014-04-07 | 2021-02-26 | 영진약품 주식회사 | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 |
| SG11201701577WA (en) * | 2014-08-29 | 2017-04-27 | Wakamoto Pharma Co Ltd | Lactic acid bacteria-containing composition |
| CA3018328A1 (fr) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methodes et compositions destinees au traitement du trouble de deficit d'attention |
| JP2018520112A (ja) * | 2015-05-26 | 2018-07-26 | オディディ，イサ | 制御持続放出プレガバリン |
| JP7021108B2 (ja) * | 2016-04-19 | 2022-02-16 | コナリス リサーチ インスティテュート アクチェンゲゼルシャフト | ニコチンアミドの経口薬学的組成物 |
| CN109475510B (zh) * | 2016-07-17 | 2023-03-10 | Mapi医药公司 | 普瑞巴林的延长释放剂型 |
| JP6919119B2 (ja) * | 2017-01-23 | 2021-08-18 | 日新製薬株式会社 | ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| CN112023032B (zh) * | 2020-09-14 | 2022-03-18 | 广东鼎信医药科技有限公司 | 一种含有消化酶的药物组合物及其制备方法 |
| KR20230117591A (ko) | 2020-12-04 | 2023-08-08 | 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. | 통증 경감을 위한 오피오이드 진통제 및 항경련제를함유하는 안정한 코팅된, 고형의 약학적 조성물 |
| CN116898819B (zh) * | 2023-06-09 | 2024-02-06 | 则正(上海)生物科技有限公司 | 一种普瑞巴林缓释剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| WO1998029095A2 (fr) * | 1997-01-03 | 1998-07-09 | Elan Corporation, Plc | Formulation de minicomprimes de cisapride a liberation prolongee |
| FR2781793B1 (fr) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
| KR20040081446A (ko) * | 2002-01-04 | 2004-09-21 | 아이박스 리서치, 인코포레이티드 | 글리피지드의 서방성을 위한 약물 전달 체계 |
| CA2477088A1 (fr) * | 2002-02-22 | 2003-10-02 | New River Pharmaceuticals Inc. | Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs |
| CA2597910A1 (fr) * | 2005-02-15 | 2006-08-24 | Jazz Pharmaceuticals, Inc. | Forme posologique et procede de liberation soutenue d'un compose pyrazine substitue |
-
2006
- 2006-01-20 AR ARP060100226A patent/AR062647A1/es not_active Application Discontinuation
- 2006-01-20 TW TW095102217A patent/TW200640497A/zh unknown
- 2006-01-20 WO PCT/US2006/001887 patent/WO2006078811A2/fr not_active Ceased
- 2006-01-20 JP JP2007552260A patent/JP2008528494A/ja active Pending
- 2006-01-20 MX MX2007008833A patent/MX2007008833A/es not_active Application Discontinuation
- 2006-01-20 KR KR1020077019105A patent/KR20070116588A/ko not_active Withdrawn
- 2006-01-20 AU AU2006206423A patent/AU2006206423A1/en not_active Abandoned
- 2006-01-20 BR BRPI0614021-1A patent/BRPI0614021A2/pt not_active IP Right Cessation
- 2006-01-20 CN CNA2006800065476A patent/CN101137352A/zh active Pending
- 2006-01-20 CA CA002595470A patent/CA2595470A1/fr not_active Abandoned
- 2006-01-20 EP EP06718892A patent/EP1838291A4/fr not_active Withdrawn
-
2007
- 2007-07-19 IL IL184735A patent/IL184735A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070116588A (ko) | 2007-12-10 |
| IL184735A0 (en) | 2007-12-03 |
| CA2595470A1 (fr) | 2006-07-27 |
| CN101137352A (zh) | 2008-03-05 |
| AU2006206423A1 (en) | 2006-07-27 |
| WO2006078811A2 (fr) | 2006-07-27 |
| EP1838291A4 (fr) | 2008-12-03 |
| EP1838291A2 (fr) | 2007-10-03 |
| TW200640497A (en) | 2006-12-01 |
| MX2007008833A (es) | 2008-03-25 |
| WO2006078811A3 (fr) | 2007-03-01 |
| JP2008528494A (ja) | 2008-07-31 |
| BRPI0614021A2 (pt) | 2011-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062647A1 (es) | Formulaciones farmaceutica y metodos de uso | |
| ES2641821T3 (es) | Forma de dosificación sólida de disolución rápida | |
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| MX2015012433A (es) | Matriz de microestructura para suministro de agentes activos. | |
| EP2422794A3 (fr) | Compositions comprenant des cellules souches embryonnaires humaines et leurs dérivés, procédés d'utilisation et procédés de préparation | |
| WO2007128923A3 (fr) | Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation | |
| AR048705A1 (es) | Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
| EP4218724A3 (fr) | Réseaux à microstructures pour l'administration d'agents actifs | |
| DE60121301D1 (de) | Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen | |
| UY27553A1 (es) | Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno | |
| AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
| HRP20060147B1 (hr) | Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu | |
| WO2008061226A3 (fr) | Formulations de topiramate à libération prolongée | |
| EP2231126A2 (fr) | Comprimé dispersible oral | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| UY29377A1 (es) | Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos. | |
| ATE504288T1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
| MX2010004388A (es) | Formulaciones de hormona paratiroidea y usos de las mismas. | |
| JP2010518086A5 (fr) | ||
| DE60128263D1 (de) | Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung | |
| US20220233833A1 (en) | Fast-dissolving microneedle | |
| PA8615501A1 (es) | Formulaciones farmaceuticas transdermicas | |
| TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
| CN101351189A (zh) | 用于治疗指（趾）甲病的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |